SRScholar Rock SRRK · NASDAQ
$39.90 -1.82% (-$0.74)
- Market cap
- $4.87B
- Enterprise value
- $4.64B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -88.8%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.62
- Free float
- 82.7%
About the company
Scholar Rock Holding Corporation is a U.S.-based biotechnology company focused on developing therapeutics that specialize in innovative approaches to modulating biological signaling pathways. The company concentrates on developing drugs that target proteins and signaling molecules involved in cell growth and development, particularly in the fields of neurology, oncology, and immunology. Scholar Rock is positioned as a leader in highly targeted therapies with the potential to transform the treatment of a range of serious and previously difficult-to-treat diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
David L. Hallal
Employees
289
Headquarters
Cambridge
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number